Table 5.

Use of cyproterone acetate (CPA, competitive antagonist at the androgen receptor) in HS.

References	Type of Source	Dose	Results	Conclusion
Sawers et al., 1986 [39]	case series (n = 4; all female)	CPA 100 mg/d + 30 to 50 µg/d ethinyl oestradio	−75% of patients had vulvar HS involvement −100% of patients showed rapid objective clinical and subjective improvement −after reduction of CPA to 50 mg/d, 75% of patients showed worsening	In HS, there is an androgen-dependent disorder. Combined cyproterone acetate and estrogen therapy in women may be useful.
Mortimer et al., 1986 [38]	randomized double-blind crossover trial (n = 24; all female)	CPA 50 mg/d + 50 µg/d ethinyl oestradio	−71% of patients had vulvar HS involvement −50% showed improvement in their disease and 30% showed complete remission over 18 months	Anti-androgen therapy may be beneficial in HS.
Kraft et al., 2007 [23]	retrospective chart review (n = 29; all female)	CPA 2 to 25 mg/d + 35 µg/d ethinyl oestradio ± spironolactone 100 mg/d	−55% of the patients showed an improvement in the HS symptoms.	Hormone treatment should be considered for women.